The purpose of this mini-review is to explore the association between depression or anxiety and the dysregulation of the ECS, and the use of phytocannabinoids and synthetic cannabinoids in the remediation of depression/anxiety symptoms. Depression is a widespread debilitating mental illness affecting approximately 300–350 million people globally [3]. Depression is often not an isolated disorder and may be co-morbid with other ailments such as anxiety, cancer, diabetes, stress, pain, and other neuropsychiatric disorders [4,5] for reviews). It is well known that other systems, such as dopamine, serotonin, opioid, adrenergic systems, are also involved in depression and anxiety, but the main focus of the present review is on the endogenous and exogenous cannabinoids in relation to depression and anxiety.
